TNFRSF8 and anaplastic large cell lymphoma: Brentuximab vedotin (BV) is an antibody targeting CD30 conjugated to the cytotoxic agent monomethyl auristatin E. The phase III ECHELON-2 trial showed that patients treated with BV, cyclophosphamide, doxorubicin, and prednisone (BV-CHP) had a superior outcome as compared with patients treated with CHOP for peripheral T-cell lymphomas, particularly anaplastic large cell lymphomas [73].